NANS

ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)

Retrieved on: 
Thursday, January 25, 2024
BCI, Assistant, Spinal cord injury, ARC, Euronext, Spinal cord, NANS, Neuromodulation, DSM-IV codes, University, Kessler Foundation, SCI, De novo, Movement, Paralysis, Neurology, FDA, Chronic pain, Abstract, Medical device

The Up-LIFT pivotal study investigated non-invasive neuromodulation to improve upper extremity strength and function after SCI; ARC-EX Therapy met all primary safety and effectiveness endpoints and demonstrated a 72% responder rate1.

Key Points: 
  • The Up-LIFT pivotal study investigated non-invasive neuromodulation to improve upper extremity strength and function after SCI; ARC-EX Therapy met all primary safety and effectiveness endpoints and demonstrated a 72% responder rate1.
  • While bringing awareness to spinal cord injury during a meeting traditionally focused on chronic pain and movement disorders, Dr.
  • Guest presented clinical results and his experience from the Up-LIFT pivotal study.
  • All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX, and ARC Therapy, alone or in combination with BCI, are investigational and not available for commercial use.

Nalu Medical, Inc. Presents Long-term and Holistic Outcomes from the COMFORT RCT for PNS at NANS 2024

Retrieved on: 
Tuesday, January 23, 2024
Neurology, Biotechnology, Physical Therapy, Surgery, Health, Medical Devices, Health Technology, Clinical Trials, North American Neuromodulation Society, Patient, PNS, Spinal cord, Research, Knee, NANS, RCT, Quality of life, Shoulder, Medicine, Pain, Spinal cord stimulator, SCS, Nerve, Chronic pain, Annual general meeting, Randomized controlled trial, Nalu, Physician, Pharmaceutical industry

The ongoing COMFORT RCT is a randomized, controlled, post-market, open-label, minimal risk, multi-center clinical study focused on evaluating the effectiveness of peripheral nerve stimulation (PNS) therapy with the Nalu Neurostimulation System to treat chronic pain in the shoulder, low back, knee, or ankle/foot.

Key Points: 
  • The ongoing COMFORT RCT is a randomized, controlled, post-market, open-label, minimal risk, multi-center clinical study focused on evaluating the effectiveness of peripheral nerve stimulation (PNS) therapy with the Nalu Neurostimulation System to treat chronic pain in the shoulder, low back, knee, or ankle/foot.
  • The study is designed to develop 3-year data to demonstrate the sustained pain relief and quality of life improvements achievable with the Nalu PNS system.
  • In the COMFORT RCT, we are measuring variables that present this broader picture.
  • “The COMFORT RCT is intended to provide reliable evidence of the sustained effectiveness and impact on quality of life provided by Nalu PNS therapy and to expand the use of Nalu PNS to patients for whom physicians have limited options.

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Retrieved on: 
Wednesday, January 17, 2024
Senior, North American Neuromodulation Society, HFX, Patient, Medicine, PST, NANS, Pain management, University, Nervous system, Spinal cord stimulator, SCS, Chronic pain, Caesars Palace, Annual general meeting, Research fellow, University of Arkansas, Plenary session, Hertz, Dentistry

REDWOOD CITY, Calif., Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.

Key Points: 
  • Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.
  • A total of 25 scientific abstracts reviewing clinical results for 10 kHz Therapy™, including four podium presentations and 21 posters, will be presented at the conference.
  • "The growing body of clinical evidence from our 25 scientific abstracts displays the substantial benefits of 10 kHz Therapy and we look forward to continuing to treat underserved patient populations suffering from debilitating chronic pain."
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024

Retrieved on: 
Tuesday, January 16, 2024
Permanent, Sutter Health, Assistant, Hope, Patient, PNS, Therapy, Research, NANS, Knee, Medicare, Foot, Poster, Ankle, Groin, Section, Pain, SPRINT, NP-hardness, Shoulder, CRPS, SPR, Treatment, Abstract, Physician, Nursing

CLEVELAND, Jan. 16, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society (NANS) Annual Meeting January 18-21 in Las Vegas.

Key Points: 
  • CLEVELAND, Jan. 16, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society (NANS) Annual Meeting January 18-21 in Las Vegas.
  • A total of 11 abstracts highlighting applications of the SPRINT® PNS System will be featured at the meeting including four posters never before presented to the industry.
  • The presentation reviews treatment costs for patients in two cohorts who started treatment either with SPRINT PNS or with a conventional brief PNS trial.
  • The poster reviews health economics and outcomes research to explore the economic implications of the use of SPRINT PNS in chronic low back pain.

Integer to Showcase Latest Innovations in Neuromodulation Miniaturization During NANS 2024 Annual Meeting

Retrieved on: 
Tuesday, January 16, 2024
Lithium, FC, Miniaturization, Caesars Palace, Annual general meeting, CRM, Medtech, MDO, NANS, Integer

PLANO, Texas, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will join medtech leaders and innovators around the world in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace in Las Vegas from Jan. 18 – 21, 2024.

Key Points: 
  • PLANO, Texas, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will join medtech leaders and innovators around the world in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace in Las Vegas from Jan. 18 – 21, 2024.
  • During NANS, attendees are invited to visit booth #127 to learn more about Integer’s latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable devices.
  • “Through miniaturization, Integer is creating the next generation of differentiated platform technologies to accelerate and de-risk OEMs’ path to market for novel implantable medical devices,” said Jim Stephens, President, CRM&N.
  • Xcellion Gen 3 FC delivers best in class battery runtime and full re-charges in as little as 30 minutes.

Saluda Medical Announces Late Breaking Data at NANS 2024 Annual Meeting

Retrieved on: 
Tuesday, January 16, 2024
Patient, Chronic pain, NANS, RCT, Spinal cord stimulator, ECAPS, Nerve, SCS, Annual general meeting, MAE

MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Saluda Medical, Inc., a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies, today announced the company's data will be presented at the North American Neuromodulation Society (NANS) 2024 Annual Meeting, taking place January 18-21.

Key Points: 
  • MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Saluda Medical, Inc., a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies, today announced the company's data will be presented at the North American Neuromodulation Society (NANS) 2024 Annual Meeting, taking place January 18-21.
  • The 3-Year EVOKE Study demonstrated superior pain relief in the closed-loop (SmartLoop™) arm versus the open-loop arm.
  • The evidence presented at NANS demonstrates SmartLoop's capability to provide long-term superior outcomes for patients as well as advance SCS therapy efficiencies for clinical practices," said Jim Schuermann, President and CEO of Saluda Medical.
  • For more information, please visit us at NANS: Saluda Medical Booth #339.

CENTER FOR PAIN MANAGEMENT WELCOMES DR. JOSHUA WELLINGTON, MD.

Retrieved on: 
Friday, September 1, 2023
Spaulding Rehabilitation Hospital, Boston Children's Hospital, Intrathecal pump, Piriformis syndrome, Beth Israel Deaconess Medical Center, Neck pain, Arthralgia, Interventional pain management, Arthritis, Medical college, Therapy, Twilight anesthesia, ITP, Cancer, North American Neuromodulation Society, American Academy, CRPS, Medicine, MS, Harvard Medical School, Public key certificate, Back pain, Rehabilitation, Medical director, Patient, Physician, Practitioner, Physical medicine and rehabilitation, Fibromyalgia, Hospital, Health, NANS, Chronic pain, Headache, Society, Targeted drug delivery, Injury, Nursing, Dentistry, Pain management, MD

INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.

Key Points: 
  • INDIANAPOLIS, Sept. 1, 2023 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Joshua Wellington, MD, MS, has joined their practice and will be seeing patients starting September 5, 2023.
  • He will be joining Center for Pain Management to lead the Targeted Drug Delivery program, which will expand patient access to quality care for Intrathecal Pump (ITP) implants.
  • Center for Pain Management, supported by American Pain Consortium, proudly serves Indiana with 7 clinics and 4 Ambulatory Surgery Centers statewide and has been treating a wide range of acute and chronic pain conditions since 1993.
  • The physicians specialize in back pain, neck pain, headache, and joint pain resulting from injuries, arthritis, cancer, fibromyalgia, failed back surgery, Complex Regional Pain Syndromes (CRPS), and other disorders.

Saluda Medical Announces Presentation of 36-Month Trial Data at NANS 2023 Annual Meeting

Retrieved on: 
Tuesday, January 17, 2023
Spinal cord, Cleveland Clinic, NANS, RCT, Clinical trial, Pain, CMS, Quality of life, Hyperreflexia, Chronic pain, North American Neuromodulation Society, IDE, Sleep, Randomized controlled trial, Research, Cleveland, Patient, ITT, Science, SCS, Doctor of Philosophy, Annual general meeting, Pharmaceutical industry, Anesthesiology, MD

ARTARMON, Australia, Jan. 17, 2023 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation, today announced that late-breaking data from the landmark EVOKE Clinical Trial was presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting. The data presented is the longest follow-up evidence from a US IDE trial in spinal cord stimulation (SCS) history.

Key Points: 
  • ARTARMON, Australia, Jan. 17, 2023 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation, today announced that late-breaking data from the landmark EVOKE Clinical Trial was presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting.
  • The data presented is the longest follow-up evidence from a US IDE trial in spinal cord stimulation (SCS) history.
  • The majority of patients who crossed over from open-loop to closed-loop therapy chose to cross over in search of better pain relief.
  • Importantly, 9 out of 10 patients treated with closed-loop at any time completed the study in the closed-loop arm.

Integer to Exhibit at NANS 2023 Annual Meeting

Retrieved on: 
Tuesday, January 10, 2023
Lithium, Medtech, NANS, North American Neuromodulation Society, NYSE, Miniaturization, Integer, MDO, Original equipment manufacturer, FC, Acquisition, Commercialization, Annual general meeting, Medical device

PLANO, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will exhibit at the 26th North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace Convention Center in Las Vegas, Nevada, from Jan. 12 – 14, 2023, joining medtech leaders and innovators from around the world.

Key Points: 
  • PLANO, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will exhibit at the 26th North American Neuromodulation Society (NANS) Annual Meeting at Caesars Palace Convention Center in Las Vegas, Nevada, from Jan. 12 – 14, 2023, joining medtech leaders and innovators from around the world.
  • Attendees are invited to visit Integer at booth #525 to learn more about Integer’s breadth and depth of innovative medical device manufacturing, design and development capabilities.
  • This encompasses expanded implantable neuromodulation lead offerings as a result of the acquisition of Oscor in December 2021.
  • During NANS, Integer will unveil its latest innovations and expanded capabilities in neuromodulation to enable the next generation of miniaturized active implantable devices.

Neuralace Medical Announces Upcoming Abstract Presentation at the 26th Annual North American Neuromodulation Society meeting (NANS) showcasing its FDA-cleared, Non-Invasive Axon Therapy® for Chronic Pain

Retrieved on: 
Friday, January 6, 2023
Chronic pain, United States Department of Veterans Affairs, SAN, Axon, NANS, Patient, Transcranial magnetic stimulation, FDA, Observational study, Location, Poultry, Pharmaceutical industry

SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Neuralace Medical, Inc., a commercial-stage medical technology company focused on innovative solutions for the treatment of chronic neuropathic pain, is announcing the upcoming presentation by the VA Augusta of its pilot study focused on assessing the impact of Axon Magnetic Peripheral Nerve Stimulation (mPNS).

Key Points: 
  • Magnetic Peripheral Nerve Stimulation (mPNS) is the proprietary mechanism of action behind Neuralace Medical's FDA-cleared Axon Therapy device.
  • The Axon device is the only FDA-cleared, non-invasive, magnetic peripheral nerve stimulation device available to patients who could benefit from peripheral neurostimulation, but for whom implantable solutions are not appropriate.
  • The presentation will occur at the 26th Annual North American Neuromodulation Society meeting (January 12-15, 2023) on Saturday January 14th at 11:10 AM PST, Location TBD.
  • Keith continued, "we are thrilled to have the results of this initial pilot study made available, and look forward to additional studies being published in 2023."